Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Bone and Mineral Research

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jbmr.1861PMID 23299909PMCID PMC3657331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• R: A language and environment for statistical computing.

  2014cited by this paper
• HIV: Inflammation and Bone

  2012cited by this paper
• Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study

  2012cited by this paper
• Bone Turnover, Osteoprotegerin/Rankl and Inflammation with Antiretroviral Initiation: Tenofovir versus Non-Tenofovir Regimens

  2011cited by this paper
• Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis

  2011cited by this paper
• Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.

  2010cited by this paper
• The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters

  2010cited by this paper
• The multiple faces of autoimmune-mediated bone loss

  2010cited by this paper
• Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women.

  2010cited by this paper
• Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves

  2010cited by this paper
• Continuous antiretroviral therapy decreases bone mineral density

  2009cited by this paper
• Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption.

  2008cited by this paper
• Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study.

  2008cited by this paper
• Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection

  2007cited by this paper
• CD4+ count-guided interruption of antiretroviral treatment.

  2006cited by this paper
• Longitudinal analysis of bone density in human immunodeficiency virus-infected women.

  2006cited by this paper
• Low bone-mineral density in patients with HIV: pathogenesis and clinical significance

  2006cited by this paper
• The role of the immune system in the pathophysiology of osteoporosis

  2005cited by this paper
• Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis

  2003cited by this paper
• Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis

  2001cited by this paper
• Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

  1999cited by this paper
• Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

  1999cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study.

  1995cited by this paper
• Metabolic bone assessment in patients with inflammatory bowel disease.

  1995cited by this paper
• Alterations in bone turnover in HIV-positive patients

  1993cited by this paper
• ALTERATIONS IN THE

  1985cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Decreased Bone Formative and Enhanced Resorptive Markers in Human Immunodeficiency Virus Infection: Indication of Normalization of the Bone-Remode

  year unknowncited by this paper

• Bone loss in young adults with HIV following antiretroviral therapy containing tenofovir disoproxil fumarate regimen using machine learning

  2025cites this paper
• The effect of anti-retroviral therapy on fracture healing

  2022cites this paper
• HIV Infection, HIV Therapy, and Bone Health

  2020cites this paper
• Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis

  2020cites this paper
• People living with HIV and fracture risk

  2020cites this paper
• Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial

  2020cites this paper
• Pharmacotherapeutic options for kidney disease in HIV positive patients

  2020cites this paper
• Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case–Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4)

  2019cites this paper
• HIV, antiretroviral therapy, pregnancy, lactation and bone health in Uganda

  2018cites this paper
• Serious Non-AIDS Conditions in HIV: Benefit of Early ART

  2018cites this paper
• The Hidden Burden of Fractures in People Living With HIV

  2018cites this paper
• Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial

  2017influential citation
• Upregulation of Apoptosis Pathway Genes in Peripheral Blood Mononuclear Cells of HIV-Infected Individuals with Antiretroviral Therapy-Associated Mitochondrial Toxicity

  2017cites this paper
• Osteoporosis and osteopenia are not associated with T-cell activation in older cART-treated HIV-infected patients.

  2017cites this paper
• Trastornos de la densidad mineral ósea en personas con VIH en tratamiento antirretroviral Pereira- Risaralda-Colombia

  2017cites this paper
• Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease

  2016cites this paper
• Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients

  2016cites this paper
• Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?

  2016cites this paper
• Does systemic inflammation and immune activation contribute to fracture risk in HIV?

  2016cites this paper
• Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients

  2016cites this paper
• Prevalence of low bone mineral density and fracture in HIV

  2015cites this paper
• Osteoprotegerin, but Not Receptor Activator for Nuclear Factor-&kgr;B Ligand, is Associated With Subclinical Coronary Atherosclerosis in HIV-Infected Men

  2015cites this paper
• Clinically Indicated Corticosteroids Do Not Affect Bone Turnover During Immune Restoration of Severely Lymphopenic HIV-Infected Patients

  2015cites this paper
• Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks

  2015cites this paper
• A Case of Hypercalcemia and Overexpression of CYP27B1 in Skeletal Muscle Lesions in a Patient with HIV Infection After Cosmetic Injections with Polymethylmethacrylate (PMMA) for Wasting

  2015cites this paper
• Skeletal health in adults with HIV infection.

  2015cites this paper
• Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.

  2015cites this paper
• Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject.

  2015cites this paper
• Mechanisms of non-AIDS complications of HIV disease: role of hepatitis C co-infection

  2015cites this paper
• Aging with HIV: osteoporosis and fractures.

  2014cites this paper
• Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapy

  2014cites this paper
• Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.

  2014cites this paper
• Capacité des protéines du VIH Tat et Nef et des inhibiteurs de la protéase virale à induire une sénescence des cellules souches mésenchymateuses de la moelle osseuse et à inhiber leur différenciation ostéoblastique

  2014cites this paper
• The effects of untreated and treated HIV infection on bone disease

  2014cites this paper
• HIV-related metabolic comorbidities in the current ART era.

  2014cites this paper
• Relationships Between Inflammation, Immune Activation, and Bone Health Among HIV-Infected Adults on Stable Antiretroviral Therapy

  2014influential citation
• Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.

  2014cites this paper
• High prevalence of low bone mass and associated factors in Korean HIV-positive male patients undergoing antiretroviral therapy

  2014influential citation
• Bone Alterations Associated with HIV

  2014cites this paper
• HIV: An underrecognized secondary cause of osteoporosis?

  2013cites this paper
• Bone: Increased fracture risk with HIV infection—a growing concern

  2013cites this paper